Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03719066 | Oct 2018 → Feb 2020 | vaccinia | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| Phase 2 | NCT01762930 | Jun 2012 → Dec 2015 | cold-induced sweating syndrome - hyperthermia spectrum | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT03581734 | Jul 2018 → Oct 2022 | vaccinia | International Centre for Diarrhoeal Disease Research, Bangladesh | Unknown | No outcome recorded |
| Phase 3 | NCT02434822 | Apr → Sep 2015 | cholera | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT02027207 | Dec 2012 → Dec 2017 | cholera | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | Met primary |
| Phase 43 trials | ||||||
| Phase 4 | NCT01949675 | Mar 2014 → Feb 2015 | cholera | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01579448 | Dec 2012 → Jul 2013 | cholera | Sachin Desai | Completed | No outcome recorded |
| Phase 4 | NCT00760825 | Mar 2012 → Apr 2013 | cholera | International Vaccine Institute | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04423159 | Oct 2016 → Oct 2020 | intestinal infectious disease | Centre for Infectious Disease Research in Zambia | Completed | No outcome recorded |
| — | NCT02499172 | Jun 2015 → Oct 2016 | cholera, pregnancy disorder with abortive outcome | Johns Hopkins Bloomberg School of Public Health | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy10 trials | ||||||
| Phase 1/2 | NCT02823899 Comparator | Jul 2016 → Nov 2017 | cholera | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | Met primary |
| Phase 2 | NCT02742558 Comparator | Apr 2016 → Jun 2017 | cholera | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 2 | NCT02145377 Comparator | Jul 2014 → Mar 2015 | cholera | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 2 | NCT01042951 Comparator | Jan → Aug 2010 | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 3 | NCT05507229 Comparator | Feb → Jul 2022 | cholera | Bharat Biotech International Limited | Unknown | No outcome recorded |
| Phase 3 | NCT04760236 Comparator | Oct 2021 → Dec 2022 | cholera | International Vaccine Institute | Completed | Met primary |
| Phase 3 | NCT02164110 Comparator | May → Sep 2014 | — | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 4 | NCT03373669 Comparator | Nov 2017 → Oct 2019 | cholera | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| — | NCT01811771 Comparator | Aug 2012 → Aug 2015 | cholera | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| — | NCT01339845 Comparator | Sep 2009 → Dec 2016 | cholera | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shanchol | “This open-label study assessed the safety and immunogenicity of two doses (14 days apart) of an indigenously manufactured, killed, bivalent (Vibrio cholerae O1 and O139),...” PMID 31211792 ↗ Jun 201923“Advantages of the Shanchol™ vaccine include that its cost is lower and does not require administration with buffer, thus making it more feasible for use in mass vaccination...” NCT02027207 ↗ “OCV has recently been introduced to Zambia where a large population was vaccinated with 1 dose of Shanchol®, and about 6 months later over 70% individuals traced to receive a...” NCT04423159 ↗ “Another whole cell killed OCV, ShancholTM, which is WHO prequalified, is based on similar bacterial components as Dukoral and licensed in India but not in Bangladesh.” NCT02742558 ↗ “Shanchol is a bivalent (O1 and O139 serotypes) vaccine using a heat-killed classical Inaba strain and a formalin-killed classical Ogawa strain produced by Sanofi.” NCT03373669 ↗ “We evaluated the effect of a killed OCV, Shanchol™, on pregnancy outcomes during an effectiveness trial of the vaccine in urban Bangladesh.” PMID 28196715 ↗ Feb 2017 “The oral cholera vaccine (OCV), Shanchol™ has shown protective efficacy lasting up to 5 years” PMID 26896684 ↗ Feb 2016 “Shanchol™, an inactivated oral cholera vaccine (OCV) is currently in use globally.” PMID 36136760 ↗ Jan 2023 “The OCV to be used in the trial is Shanchol.” NCT03719066 ↗ |
| Known as | ShancholTM | “Another whole cell killed OCV, ShancholTM, which is WHO prequalified, is based on similar bacterial components as Dukoral and licensed in India but not in Bangladesh.” NCT02742558 ↗ |
| Modality | Vaccine | “whole-cell oral cholera vaccine” NCT00760825 ↗ |
| Route | Oral | “1.5 ml given twice orally, 14 days apart” NCT00760825 ↗ |